<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02305277</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-91067-119</org_study_id>
    <nct_id>NCT02305277</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers</brief_title>
  <official_title>Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-centre, open-label, randomised, three-part, two-way crossover study in 84 healthy
      volunteers. In each part, the study consisted of two consecutive single-dose treatment
      periods separated by a washout period of at least 14 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax - Maximum Observed Plasma Concentration</measure>
    <time_frame>before OPC dosing, and ½, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-OPC dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-t - Area Under the Plasma Concentration-time Curve for BIA 9-1067</measure>
    <time_frame>before OPC dosing, and ½, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-OPC dose</time_frame>
    <description>Area Under the plasma concentration-time Curve from time 0 to the time of last quantifiable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax - Time of Occurrence of Cmax</measure>
    <time_frame>before OPC dosing, and ½, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-OPC dose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Parkinson</condition>
  <arm_group>
    <arm_group_label>BIA 9-1067 5 mg Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>volunteers received a single oral dose of 5 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation
CM - clinical micronized TBM - to-be-marketed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIA 9-1067 25 mg Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>volunteers received a single oral dose of 25 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation
CM - clinical micronized TBM - to-be-marketed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIA 9-1067 50 mg Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>volunteers received a single oral dose of 50 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation
CM - clinical micronized TBM - to-be-marketed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIA 9-1067 5 mg Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>volunteers received a single oral dose of 5 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation
CM - clinical micronized TBM - to-be-marketed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIA 9-1067 25 mg Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>volunteers received a single oral dose of 25 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation
CM - clinical micronized TBM - to-be-marketed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIA 9-1067 50 mg Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>volunteers received a single oral dose of 50 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation
CM - clinical micronized TBM - to-be-marketed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 9-1067 (clinical micronized, CM)</intervention_name>
    <arm_group_label>BIA 9-1067 5 mg Sequence 1</arm_group_label>
    <arm_group_label>BIA 9-1067 25 mg Sequence 1</arm_group_label>
    <arm_group_label>BIA 9-1067 50 mg Sequence 1</arm_group_label>
    <arm_group_label>BIA 9-1067 5 mg Sequence 2</arm_group_label>
    <arm_group_label>BIA 9-1067 25 mg Sequence 2</arm_group_label>
    <arm_group_label>BIA 9-1067 50 mg Sequence 2</arm_group_label>
    <other_name>OPC, Opicapone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 9-1067 (to-be-marketed, TBM)</intervention_name>
    <arm_group_label>BIA 9-1067 5 mg Sequence 1</arm_group_label>
    <arm_group_label>BIA 9-1067 25 mg Sequence 1</arm_group_label>
    <arm_group_label>BIA 9-1067 50 mg Sequence 1</arm_group_label>
    <arm_group_label>BIA 9-1067 5 mg Sequence 2</arm_group_label>
    <arm_group_label>BIA 9-1067 25 mg Sequence 2</arm_group_label>
    <arm_group_label>BIA 9-1067 50 mg Sequence 2</arm_group_label>
    <other_name>OPC, Opicapone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A signed and dated informed consent form before any study-specific screening procedure
             was performed;

          -  Male or female subjects aged 18 to 45 years, inclusive;

          -  Body mass index (BMI) between 18 and 30 kg/m2 inclusive;

          -  Healthy as determined by pre-study medical history, physical examination, vital signs,
             complete neurological examination and 12-lead electrocardiogram (ECG);

          -  Negative tests for hepatitis B surface antigen (HBsAg), anti- hepatitis C virus
             antibodies (HCV Ab) and anti-human immunodeficiency virus antibodies (HIV-1 and HIV-2
             Ab) at screening;

          -  Clinical laboratory test results clinically acceptable at screening and admission to
             each treatment period;

          -  Negative screen for alcohol and drugs of abuse at screening and admission to each
             treatment period;

          -  Non-smokers or ex-smokers for at least 3 months;

          -  Able to participate, and willing to give written informed consent and comply with the
             study restrictions.

          -  If female:

          -  She was not of childbearing potential by reason of surgery or, if of childbearing
             potential, she used an effective non-hormonal method of contraception [intrauterine
             device or intrauterine system; condom or occlusive cap (diaphragm or cervical or vault
             caps) with spermicidal foam or gel or film or cream or suppository; true abstinence;
             or vasectomized male partner, provided that he was the sole partner of that subject]
             for all the duration of the study;

          -  She had a negative serum pregnancy test at screening and a negative urine pregnancy
             test at admission to each treatment period.

        Exclusion Criteria:

          -  Subjects who had a clinically relevant history or presence of respiratory,
             gastrointestinal, renal, hepatic, haematological, lymphatic, neurological,
             cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological,
             dermatological, endocrine, connective tissue diseases or disorders, or had a
             clinically relevant surgical history;

          -  Had clinically relevant findings in laboratory tests, particularly any abnormality in
             the coagulation tests, or any abnormality in the liver function tests;

          -  Had a history of relevant atopy or drug hypersensitivity;

          -  Had a history of alcoholism and/or drug abuse;

          -  Consumed more than 14 units of alcohol per week [1 unit of alcohol = 280 mL beer
             (3-4°) = 100 mL wine (10-12°) = 30 mL spirits (40°)];

          -  Had a significant infection or known inflammatory process on screening or admission to
             each treatment period;

          -  Had acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at
             the time of screening or admission to each treatment period;

          -  Had used medicines within 2 weeks of admission to first period that could affect the
             safety or other study assessments, in the Investigator's opinion;

          -  Had previously received opicapone;

          -  Had used any investigational drug or participated in any clinical trial within 90 days
             prior to screening;

          -  Had participated in more than 2 clinical trials within the 12 months prior to
             screening;

          -  Had donated or received any blood or blood products within the 3 months prior to
             screening;

          -  Were vegetarians, vegans or had medical dietary restrictions;

          -  Could not communicate reliably with the Investigator;

          -  Were unlikely to co-operate with the requirements of the study;

          -  Were unwilling or unable to give written informed consent;

        If female:

          -  She was pregnant or breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2014</study_first_submitted>
  <study_first_submitted_qc>November 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2014</study_first_posted>
  <results_first_submitted>July 22, 2015</results_first_submitted>
  <results_first_submitted_qc>October 14, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 17, 2015</results_first_posted>
  <last_update_submitted>October 14, 2015</last_update_submitted>
  <last_update_submitted_qc>October 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opicapone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BIA 9-1067 5 mg Sequence 1</title>
          <description>volunteers received a single oral dose of 5 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation
CM - clinical micronized TBM - to-be-marketed
BIA 9-1067 (clinical micronized, CM)
BIA 9-1067 (to-be-marketed, TBM)</description>
        </group>
        <group group_id="P2">
          <title>BIA 9-1067 25 mg Sequence 1</title>
          <description>volunteers received a single oral dose of 25 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation
CM - clinical micronized TBM - to-be-marketed
BIA 9-1067 (clinical micronized, CM)
BIA 9-1067 (to-be-marketed, TBM)</description>
        </group>
        <group group_id="P3">
          <title>BIA 9-1067 50 mg Sequence 1</title>
          <description>volunteers received a single oral dose of 50 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation
CM - clinical micronized TBM - to-be-marketed
BIA 9-1067 (clinical micronized, CM)
BIA 9-1067 (to-be-marketed, TBM)</description>
        </group>
        <group group_id="P4">
          <title>BIA 9-1067 5 mg Sequence 2</title>
          <description>volunteers received a single oral dose of 5 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation
CM - clinical micronized TBM - to-be-marketed
BIA 9-1067 (clinical micronized, CM)
BIA 9-1067 (to-be-marketed, TBM)</description>
        </group>
        <group group_id="P5">
          <title>BIA 9-1067 25 mg Sequence 2</title>
          <description>volunteers received a single oral dose of 25 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation
CM - clinical micronized TBM - to-be-marketed
BIA 9-1067 (clinical micronized, CM)
BIA 9-1067 (to-be-marketed, TBM)</description>
        </group>
        <group group_id="P6">
          <title>BIA 9-1067 50 mg Sequence 2</title>
          <description>volunteers received a single oral dose of 50 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation
CM - clinical micronized TBM - to-be-marketed
BIA 9-1067 (clinical micronized, CM)
BIA 9-1067 (to-be-marketed, TBM)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received CM</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received TBM</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BIA 9-1067 5 mg Sequence 1</title>
          <description>volunteers received a single oral dose of 5 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation
CM - clinical micronized TBM - to-be-marketed
BIA 9-1067 (clinical micronized, CM)
BIA 9-1067 (to-be-marketed, TBM)</description>
        </group>
        <group group_id="B2">
          <title>BIA 9-1067 25 mg Sequence 1</title>
          <description>volunteers received a single oral dose of 25 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation
CM - clinical micronized TBM - to-be-marketed
BIA 9-1067 (clinical micronized, CM)
BIA 9-1067 (to-be-marketed, TBM)</description>
        </group>
        <group group_id="B3">
          <title>BIA 9-1067 50 mg Sequence 1</title>
          <description>volunteers received a single oral dose of 50 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation
CM - clinical micronized TBM - to-be-marketed
BIA 9-1067 (clinical micronized, CM)
BIA 9-1067 (to-be-marketed, TBM)</description>
        </group>
        <group group_id="B4">
          <title>BIA 9-1067 5 mg Sequence 2</title>
          <description>volunteers received a single oral dose of 5 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation
CM - clinical micronized TBM - to-be-marketed
BIA 9-1067 (clinical micronized, CM)
BIA 9-1067 (to-be-marketed, TBM)</description>
        </group>
        <group group_id="B5">
          <title>BIA 9-1067 25 mg Sequence 2</title>
          <description>volunteers received a single oral dose of 25 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation
CM - clinical micronized TBM - to-be-marketed
BIA 9-1067 (clinical micronized, CM)
BIA 9-1067 (to-be-marketed, TBM)</description>
        </group>
        <group group_id="B6">
          <title>BIA 9-1067 50 mg Sequence 2</title>
          <description>volunteers received a single oral dose of 50 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation
CM - clinical micronized TBM - to-be-marketed
BIA 9-1067 (clinical micronized, CM)
BIA 9-1067 (to-be-marketed, TBM)</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="14"/>
            <count group_id="B5" value="14"/>
            <count group_id="B6" value="14"/>
            <count group_id="B7" value="85"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Maximum Observed Plasma Concentration</title>
        <time_frame>before OPC dosing, and ½, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-OPC dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIA 9-1067 5 mg CM</title>
            <description>BIA 9-1067 5 mg CM CM - clinical micronized</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 5 mg TBM</title>
            <description>BIA 9-1067 5 mg TBM TBM - to-be-marketed</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 25 mg CM</title>
            <description>BIA 9-1067 25 mg CM CM - clinical micronized</description>
          </group>
          <group group_id="O4">
            <title>BIA 9-1067 25 mg TBM</title>
            <description>BIA 9-1067 25 mg TBM TBM - to-be-marketed</description>
          </group>
          <group group_id="O5">
            <title>BIA 9-1067 50 mg CM</title>
            <description>BIA 9-1067 50 mg CM CM - clinical micronized</description>
          </group>
          <group group_id="O6">
            <title>BIA 9-1067 50 mg TBM</title>
            <description>BIA 9-1067 50 mg TBM TBM - to-be-marketed</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Maximum Observed Plasma Concentration</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.3" spread="55.7"/>
                    <measurement group_id="O2" value="95.5" spread="37.8"/>
                    <measurement group_id="O3" value="424.5" spread="155.7"/>
                    <measurement group_id="O4" value="471.0" spread="206.9"/>
                    <measurement group_id="O5" value="756.2" spread="302.4"/>
                    <measurement group_id="O6" value="802.9" spread="363.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-t - Area Under the Plasma Concentration-time Curve for BIA 9-1067</title>
        <description>Area Under the plasma concentration-time Curve from time 0 to the time of last quantifiable concentration</description>
        <time_frame>before OPC dosing, and ½, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-OPC dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIA 9-1067 5 mg CM</title>
            <description>BIA 9-1067 5 mg CM CM - clinical micronized</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 5 mg TBM</title>
            <description>BIA 9-1067 5 mg TBM TBM - to-be-marketed</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 25 mg CM</title>
            <description>BIA 9-1067 25 mg CM CM - clinical micronized</description>
          </group>
          <group group_id="O4">
            <title>BIA 9-1067 25 mg TBM</title>
            <description>BIA 9-1067 25 mg TBM TBM - to-be-marketed</description>
          </group>
          <group group_id="O5">
            <title>BIA 9-1067 50 mg CM</title>
            <description>BIA 9-1067 50 mg CM CM - clinical micronized</description>
          </group>
          <group group_id="O6">
            <title>BIA 9-1067 50 mg TBM</title>
            <description>BIA 9-1067 50 mg TBM TBM - to-be-marketed</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - Area Under the Plasma Concentration-time Curve for BIA 9-1067</title>
          <description>Area Under the plasma concentration-time Curve from time 0 to the time of last quantifiable concentration</description>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196.8" spread="128.5"/>
                    <measurement group_id="O2" value="197.7" spread="89.7"/>
                    <measurement group_id="O3" value="1137" spread="413.8"/>
                    <measurement group_id="O4" value="1270" spread="515.5"/>
                    <measurement group_id="O5" value="2043" spread="1032"/>
                    <measurement group_id="O6" value="2161" spread="1110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax - Time of Occurrence of Cmax</title>
        <time_frame>before OPC dosing, and ½, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-OPC dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIA 9-1067 5 mg CM</title>
            <description>BIA 9-1067 5 mg CM CM - clinical micronized</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 5 mg TBM</title>
            <description>BIA 9-1067 5 mg TBM TBM - to-be-marketed</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 25 mg CM</title>
            <description>BIA 9-1067 25 mg CM CM - clinical micronized</description>
          </group>
          <group group_id="O4">
            <title>BIA 9-1067 25 mg TBM</title>
            <description>BIA 9-1067 25 mg TBM TBM - to-be-marketed</description>
          </group>
          <group group_id="O5">
            <title>BIA 9-1067 50 mg CM</title>
            <description>BIA 9-1067 50 mg CM CM - clinical micronized</description>
          </group>
          <group group_id="O6">
            <title>BIA 9-1067 50 mg TBM</title>
            <description>BIA 9-1067 50 mg TBM TBM - to-be-marketed</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax - Time of Occurrence of Cmax</title>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O4" value="2.00" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O5" value="2.00" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O6" value="2.00" lower_limit="1.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>BIA 9-1067 5 mg CM</title>
          <description>BIA 9-1067 5 mg CM CM - clinical micronized</description>
        </group>
        <group group_id="E2">
          <title>BIA 9-1067 5 mg TBM</title>
          <description>BIA 9-1067 5 mg TBM TBM - to-be-marketed</description>
        </group>
        <group group_id="E3">
          <title>BIA 9-1067 25 mg CM</title>
          <description>BIA 9-1067 25 mg CM CM - clinical micronized</description>
        </group>
        <group group_id="E4">
          <title>BIA 9-1067 25 mg TBM</title>
          <description>BIA 9-1067 25 mg TBM TBM - to-be-marketed</description>
        </group>
        <group group_id="E5">
          <title>BIA 9-1067 50 mg CM</title>
          <description>BIA 9-1067 50 mg CM CM - clinical micronized</description>
        </group>
        <group group_id="E6">
          <title>BIA 9-1067 50 mg TBM</title>
          <description>BIA 9-1067 50 mg TBM TBM - to-be-marketed</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research</name_or_title>
      <organization>Bial – Portela &amp; Cª, S.A.</organization>
      <phone>+351 229 866 100</phone>
      <email>jose.rocha@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

